Website: Pluristyx
Business Area(s): 

Pluristyx was established in 2018 with the primary goal of manufacturing clinical-grade pluripotent stem cells at scale under GMP. Responding to industry needs, Pluristyx merged with Cyathlon Biosciences to form a single complementary business entity to not only provide pluripotent stem cells for clinical development, but also stem cell contract development and manufacturing services along with the necessary tools and knowledge support to companies in the field of drug development, regenerative medicine, and cellular and gene-modified cellular therapies.

Seattle WA
United States